Journal issues > Issue 5, September 2023 > Highlights in chronic myeloid leukaemia

Highlights in chronic myeloid leukaemia

SUMMARY

The focus on CML this year was on how to improve patient’s eligibility and success of treatment free remission (TFR). The longest TFR follow-up comes from the STIM trial, Imatinib +/- Interferon (IFN), in which has been shown that at 7-year follow-up only 38% of patients maintain TFR.¹ Previously, additional prognostic features such as IFN pre-treatment and increased NK cell count at baseline have been suggested to be associated with increased success of TFR however these are not always validated in larger cohorts. Several investigators are therefore looking at how to better define TFR eligible patients and at how to increase the TFR success rate.

(BELG J HEMATOL 2023;14(5):207–10)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top